Titanovo Logo
Back to Cell Types

MOLM-13Homo sapiens (Human)Cancer cell line

Also known as: Molm 13, Molm13, MOLM13

🤖 AI SummaryBased on 12 publications

Quick Overview

MOLM-13 is a human acute myeloid leukemia cell line derived from MDS with FLT3-ITD mutation, used in cancer research.

Detailed Summary

MOLM-13 is a human acute myeloid leukemia (AML) cell line established from a patient with myelodysplastic syndrome (MDS) that progressed to AML. It is characterized by the presence of the FLT3-ITD mutation, a common genetic alteration in AML that leads to constitutive activation of the FLT3 tyrosine kinase receptor. This cell line is widely used in research to study the molecular mechanisms of FLT3-driven leukemias and to evaluate therapeutic strategies targeting FLT3. MOLM-13 has been utilized in studies investigating resistance mechanisms to FLT3 inhibitors, such as the emergence of secondary D835Y mutations. Additionally, it has been employed in studies examining the role of cohesin complex mutations in myeloid malignancies and in evaluating the efficacy of BET inhibitors and other targeted therapies. The cell line is also used in studies related to epigenetic regulation and drug sensitivity profiling.

Research Applications

FLT3-ITD mutation studiesFLT3 inhibitor resistance mechanismsCohesin complex mutations in myeloid malignanciesBET inhibitor efficacy testingEpigenetic regulation studiesDrug sensitivity profiling

Key Characteristics

FLT3-ITD mutationResistance to FLT3 inhibitorsCohesin complex mutationsEpigenetic alterationsHigh drug sensitivity profiles
Generated on 6/18/2025

Basic Information

Database IDCVCL_2119
SpeciesHomo sapiens (Human)
Tissue SourcePeripheral blood[UBERON:UBERON_0000178]

Donor Information

Age20
Age CategoryAdult
SexMale

Disease Information

DiseaseAcute myeloid leukemia
LineageMyeloid
SubtypeAcute Myeloid Leukemia
OncoTree CodeAML

DepMap Information

Source TypeDSMZ
Source IDACH-000362_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationUnexplicitFLT3Internal tandem duplication (FLT3-ITD)Unspecified-PubMed=12529668
Gene fusionKMT2AKMT2A-MLLT3, MLL-MLLT3, MLL-AF9--PubMed=31701557

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
10
D13S317
10,11
D16S539
10,11
D18S51
13,15
D19S433
12,14
D21S11
30,31
D2S1338
23,25
D3S1358
15
D5S818
10,11
D7S820
10,12
D8S1179
13,14
FGA
21,23
Penta D
9,12
Penta E
18,19
TH01
7
TPOX
8
vWA
16,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Changes in apoptotic pathways in MOLM-13 cell lines after induction of resistance to hypomethylating agents.

Sulova Z., Breier A.

Int. J. Mol. Sci. 22:2076.1-2076.24(2021).

DOIPubMedPMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOIPubMedPMC

The LL-100 panel: 100 cell lines for blood cancer studies.";

MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.

Sci. Rep. 9:8218-8218(2019).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

DOIPubMedPMC

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

DOIPubMedPMC

The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.

Gerstberger T., Zuber J., Savarese F., Kraut N.

Oncogene 37:2687-2701(2018).

DOIPubMedPMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene.

Pigazzi M., Martelli A.M., Basso G., Locatelli F., Pession A.

J. Hematol. Oncol. 10:26.1-26.5(2017).

DOIPubMedPMC

Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.

Chung Y.-J., Lee J.-H.

Oncotarget 8:11748-11762(2017).

DOIPubMedPMC

Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia.

Campos D., Granada I., Junca J., Drexler H.G., Sole F., Buschbeck M.

Genes Chromosomes Cancer 56:243-252(2017).

DOIPubMed

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.

Haferlach T., Shirahige K., Miyano S., Ogawa S.

Nat. Genet. 45:1232-1237(2013).

DOIPubMed

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.

Raynaud F.I., Eccles S.A., Linardopoulos S.

Leukemia 26:1462-1470(2012).

DOIPubMedPMC

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.

Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.

Leukemia 20:471-476(2006).

DOIPubMed

Identification of two MLL-MLLT3 (alias MLL-AF9) chimeric transcripts in the MOLM-13 cell line.

Pession A.

Cancer Genet. Cytogenet. 154:96-97(2004).

DOIPubMed

Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations.

Drexler H.G., Quentmeier H., MacLeod R.A.F.

Leukemia 18:227-232(2004).

DOIPubMed

FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.

Tsuchida M., Sugita K., Ida K., Hayashi Y.

Blood 103:1085-1088(2004).

DOIPubMed

FLT3 mutations in acute myeloid leukemia cell lines.";

Quentmeier H., Reinhardt J., Zaborski M., Drexler H.G.

Leukemia 17:120-124(2003).

DOIPubMed

Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000), 255-262.

Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.

Leuk. Res. 25:275-278(2001).

DOIPubMed

Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.

Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.

Leuk. Res. 24:255-262(2000).

DOIPubMed

p53 alterations in human leukemia-lymphoma cell lines: in vitro artifact or prerequisite for cell immortalization?

Uphoff C.C.

Leukemia 14:198-206(2000).

DOIPubMed

Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children.

Kobayashi M., Bessho F., Yanagisawa M., Hayashi Y.

Br. J. Haematol. 105:155-162(1999).

DOIPubMed

Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23).

Katayama Y., Kimura G., Fujii N., Omoto E., Harada M., Orita K.

Leukemia 11:1469-1477(1997).

DOIPubMed

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

DOI

Web Resources

tcpaportal.org